SIV

Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial

Retrieved on: 
Thursday, February 29, 2024

THE WOODLANDS, TX, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced it has entered into a clinical site agreement with “АКFА MEDLINE" Ltd., for its PoC human clinical trial evaluating the use of transvascular RF ablation for the treatment of pancreatic cancer pain.

Key Points: 
  • Additionally, Autonomix announced the selection of Clinical Accelerator and Qmed, full service Clinical Research Organizations (CROs) specializing in medical devices to support the PoC human clinical trial.
  • Clinical Accelerator will be responsible for managing the clinical operations in country, including recruiting patients, SIV work, and patient treatment records and Qmed will be responsible for managing protocol and trial reporting, as well as managing patient data.
  • Lori Bisson, Chief Executive Officer of Autonomix commented, “We are pleased to execute these important agreements and final steps towards commencing patient enrollment in our first PoC human clinical trial.
  • Twenty (20) subjects will be enrolled at one clinical trial site for the trial.

Oakland Zoo Provides Care for Recently Seized Marmoset Monkey

Retrieved on: 
Thursday, February 8, 2024

OAKLAND, Calif., Feb. 8, 2024 /PRNewswire-PRWeb/ -- On January 20th, Oakland Zoo worked with the California Department of Fish and Wildlife (CDFW) and the Wildlife Confiscation Network (WCN) to rescue an illegally owned female marmoset in a seizure of the monkey from a private residence in southern California. The owner was arrested on other charges unrelated to having the female marmoset and was made aware in advance that the animal was to be seized by authorities. Oakland Zoo was contacted after San Diego Zoo and Los Angeles Zoo (other Association of Zoos and Aquariums accredited partners) could not take in the marmoset due to the capacity concerns related to other WCN rescues they were involved with.

Key Points: 
  • Oakland Zoo is caring for a female marmoset named Estrela, an illegally owned pet, after being seized by California Department of Fish and Wildlife officials.
  • Oakland Zoo was contacted after San Diego Zoo and Los Angeles Zoo (other Association of Zoos and Aquariums accredited partners) could not take in the marmoset due to the capacity concerns related to other WCN rescues they were involved with.
  • Estrela will remain in the care of the Oakland Zoo and housed in their Veterinary Hospital until she has completed her quarantine period.
  • For years, animals confiscated by officials at SFO, and the Port of Oakland have been brought to Oakland Zoo for treatment, care, and permanent sanctuary.

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-500 for the Treatment of Human Immunodeficiency Virus

Retrieved on: 
Monday, November 20, 2023

HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.

Key Points: 
  • HOOKIPA is responsible for advancing the HIV program through the completion of a Phase 1b clinical trial.
  • The analyses published were conducted with a simian immunodeficiency virus (SIV) model, commonly used in a preclinical setting as a surrogate to HIV.
  • One vector is based on lymphocytic choriomeningitis virus (LCMV) as its arenaviral backbone; another vector is based on Pichinde virus (PICV).
  • HB-500 is one of two separate development programs in HOOKIPA’s collaboration and license agreement with Gilead.

ABVC BioPharma Reports Third Quarter 2023 Financial and Operational Results

Retrieved on: 
Wednesday, November 15, 2023

FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.

Key Points: 
  • FREMONT, CA, Nov. 15, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"): Today, a biotechnology company specializing in botanically based solutions that deliver high efficacy and low toxicity to improve health outcomes announced its financial and operating results for the third quarter of 2023.
  • During July 2023, the warrant exercise price was reset to $3.5 under the issuance of common stock about securities purchase agreement on July 2023.
  • During the third quarter of 2023, the Company issued to Zhonghui an aggregate of 370,000 shares of the Company's common stock at a per-share price of $20.
  • "We are delighted with our remarkable accomplishments and meaningful progress in 2023, and look forward to upcoming reports to end 2023 on a positive note," said Uttam Patil, Ph.D., Chief Executive Officer of ABVC BioPharma.

Can HIV be cured using gene editing? We will soon find out

Retrieved on: 
Wednesday, November 8, 2023

To catch this virus was initially a death sentence, but today, thanks to antiretroviral drugs, it can be kept in check.

Key Points: 
  • To catch this virus was initially a death sentence, but today, thanks to antiretroviral drugs, it can be kept in check.
  • A small biotech company in San Francisco called Excision BioTherapeutics is trying to change that with its infusion, called EBT-101.
  • Despite the availability of antiretroviral drugs, hundreds of thousands of people still die from Aids each year.
  • Testing on larger groups of people and making the therapy affordable for everyone with HIV are crucial because the disease is more prevalent in poorer countries.

Indium Tin Oxide Market size to increase by USD 213.87 million between 2022 to 2027| Amalgamated Metal Corp. PLC, American Elements, Diamond Coatings Inc. and more among key companies- Technavio

Retrieved on: 
Wednesday, September 27, 2023

Increasing dependency on renewable energy sources is notably driving the indium tin oxide market.

Key Points: 
  • Increasing dependency on renewable energy sources is notably driving the indium tin oxide market.
  • Buy the report now for detailed company information
    Indium Tin Oxide Market 2023-2027: Company Analysis:
    Ulvac Inc.: The company offers indium tin oxide products such as NE 5700 and SIV series systems.
  • View Free PDF Sample Report
    Indium Tin Oxide Market 2023-2027: Market Dynamics:
    Driver - The increasing usage of touchscreen devices is a key factor driving market growth.
  • For more information on drivers, trends and challenges, download the free sample report here
    Indium Tin Oxide Market 2023-2027: Key Highlights
    How do the major trends impact the market?

Excision BioTherapeutics Announces Gene Therapy Publication of Pre-Clinical Data Supporting its First-in-Class CRISPR-Based Gene Therapy Candidate Designed to Functionally Cure HIV-1

Retrieved on: 
Thursday, August 17, 2023

The data support the safety, biodistribution, and on-target editing of Excision’s EBT-101 program targeting HIV, which is being evaluated in first-in-human Phase 1/2 clinical trials.

Key Points: 
  • The data support the safety, biodistribution, and on-target editing of Excision’s EBT-101 program targeting HIV, which is being evaluated in first-in-human Phase 1/2 clinical trials.
  • “We are very excited by the positive data generated in this study, which set the foundation for an important first-in-human clinical trial of our lead candidate, EBT-101,” said Daniel Dornbusch, Chief Executive Officer of Excision.
  • The newly published data supplement the efficacy data generated in previous pre-clinical studies of EBT-101, demonstrating excision of integrated proviral SIV DNA in vivo, without any detectable off-target effects.
  • “These newly published results demonstrate the tremendous potential of EBT-101 to shape the future of HIV therapeutics,” said Dr. Khalili.

ABVC Corporate Update and CEO's Letter to Shareholders

Retrieved on: 
Monday, August 7, 2023

FREMONT, CA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today published a Corporate Update and Letter to Shareholders from recently appointed Chief Executive Officer, Dr. Uttam Patil.

Key Points: 
  • FREMONT, CA, Aug. 07, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire - ABVC BioPharma, Inc. (NASDAQ: ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, neurology, and oncology/hematology, today published a Corporate Update and Letter to Shareholders from recently appointed Chief Executive Officer, Dr. Uttam Patil.
  • As we move into the second half of 2023, I am delighted to speak about ABVC's recent developments and plans.
  • ABVC and BioFirst Corporation expect to complete the facility's construction in Hsinchu Biomedical Science Park, Taiwan, in 2024.
  • The product is ready for an End-of-Phase II meeting with the FDA to finalize the protocol for Phase III trials.

Alumobility to Reveal Study Findings that Showcase Benefits of Converting Steel Intensive Vehicle Body in White to Fully Aluminum

Retrieved on: 
Tuesday, June 27, 2023

ZURICH, June 27, 2023 /PRNewswire/ -- Alumobility, a global association committed to helping advance the adoption of aluminum by automakers, is presenting a webinar that reveals the benefits of converting a steel-intensive body-in-white (BIW) to a fully aluminum BIW. The presentation is based on a recent technical case study conducted by the association.

Key Points: 
  • ZURICH, June 27, 2023 /PRNewswire/ -- Alumobility, a global association committed to helping advance the adoption of aluminum by automakers, is presenting a webinar that reveals the benefits of converting a steel-intensive body-in-white (BIW) to a fully aluminum BIW.
  • The presentation is based on a recent technical case study conducted by the association.
  • "Our goal is to inform the automotive industry on the benefits of aluminum, which is the material of choice for producing lighter, safer, smarter and more sustainable vehicles."
  • The study was conducted in conjunction with a leading global automaker, using one of its latest steel intensive mixed material production battery electric vehicles (BEV) BIW structures.

Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, May 11, 2023

EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate and clinical updates.

Key Points: 
  • We recently observed durable neutralizing antibody titers at 6 months following samRNA vaccination in over 100 vaccine-naïve subjects treated within our CORAL-CEPI trial, where interim results were presented at ECCMID 2023.
  • As of May 10, 2023, the company had randomized 71 of the initially planned 80 total patients.
  • Both datasets were presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023).
  • In February 2023, results from a preclinical study conducted in collaboration with Gilead were presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2023.